Personalized Therapeutics for CNS Inflammation And Autoimmune Disorders Using Neo7Logix Precision-Based Immuno-Molecular Augmentation
Md Shamsuddin Sultan Khan 1*, Anton Yuryev 2, John Catanzaro 3
Journal of Precision Biosciences 1 (1) 1-8 https://doi.org/10.25163/biosciences.112087DB112921119
Submitted: 11 October 2019 Revised: 29 October 2019 Published: 02 November 2019
Background: The Precision-Based Immuno-Molecular Augmentation (PBIMA) technology represents an advanced, multi-purpose vaccine design approach, targeting cancer, autoimmune diseases, neurodegenerative disorders, and inflammation-driven conditions. PBIMA utilizes extensive molecular and genetic data to personalize therapy, aiming for enhanced precision and effectiveness. This study explores the application of PBIMA for personalized therapeutic interventions in progressive central nervous system (CNS) inflammation and autoimmune diseases. Methods: PBIMA leverages next-generation sequencing (NGS) data, including whole-exome sequencing (WES), whole-genome sequencing (WGS), and RNA sequencing, to identify genetic predispositions and autoantigens. The technology integrates patient-specific data for designing personalized vaccines through reverse vaccination strategies. This process includes peptide selection from self-antigen sequences and the administration of regulatory T cells and cytokines. Results: Genetic analysis revealed variants associated with autoimmune disorders, particularly affecting the IL6R, IL6ST, and TNFRSF1B genes, linked to demyelination and CSF leaks. The personalized PBIMA approach successfully identified autoantigens and employed reverse vaccination to promote immune tolerance, targeting specific pathways involved in disease progression. Conclusion: The Neo7Logix PBIMA strategy demonstrated potential in personalizing therapy for complex autoimmune conditions involving CNS inflammation. The tailored approach effectively addressed genetic predispositions and autoantigen targets, highlighting the promise of reverse vaccination in managing autoimmune diseases. Future research should refine epitope selection, optimize protocols, and validate efficacy across diverse patient cohorts.
Keywords: Precision Medicine, Neo7Logix PBIMA, Autoimmune Diseases, CNS Inflammation, Reverse Vaccination
Patient is a > 50 year old female with CNS Syrinx, neuronal inflammation and autoimmune autoantibody reactivity. She has a history of progressive intermittent seizures, fluid leakage from ears, eyes, nose and throat and progressive global fatigue and weakness.
Neo7Logix Precision-Based Immuno-Molecular Augmentation (PBIMA) approach can facilitate naïve T cells either to induce deletion of naïve T cells specific for the peptides composing the vaccine or induce differentiation of T cells with regulatory properties. These regulatory T-cells have the potential to inhibit pathogenic inflammatory (Th1) memory T cells and exert linked suppression by blocking the differentiation of naïve T cells that recognize self-antigens released because of tissue damage via epitope spreading. PBIMA can also directly at the level of memory T cells promote anergy and cause clone deletion. Targeted immunosuppression is used to deactivate immune system attacking patient organs in case of autoimmune disease. This deactivation must be aimed against possible protein targets for auto-antibodies or memory T-cells developed in patients with autoimmune disorders. Autoantibody targets can be proteins secreted by organs under attack or plasma membrane proteins in affected tissue cells. Autoimmunity can develop due to the appearance of cryptic epitopes during tissue damage. Such cryptic epitopes are hidden from T-reg education in thymus and therefore have the ability to activate immune response when they become exposed during tissue damage. Search for potential auto-antibody targets begins with analysis of patient genotype measured by WES to find proteins encoded by homozygous alleles. List of homozygous proteins is then compared with the list of proteins linked in scientific literature to autoimmune diseases related to patient condition. Proteins with patient allele that was linked to patient autoimmune condition in scientific literature are ranked higher.
To induce targeted immune-suppression, peptides are calculated from self-antigen sequences and then administered into patient in the presence of known physiological immune-suppressors such as cytokine IL10 or CD25+ regulatory T-lymphocytes isolated from patient blood and proliferated in vitro prior to vaccinations. This ensures production of soluble MHC molecules bound to peptides from vaccine [8]. Such soluble MHC molecules down-regulate memory T-cells and B-cells activated in patients with autoimmune condition directly or through intramolecular epitope spreading to cryptic determinants.
Figure 1: Suppressing autoimmunity by reverse vaccination
We focused on two pathological processes in the patient:
Demyelination symptoms were considered secondary to CSF leaks and caused by CSF material inducing autoimmune reaction in the patient. CSF leaks can be due to recessive genetic predisposition for weak dura mater. We excluded intracranial hypertension as possible cause of CSF leaks because of patient history. Structural dura mater weakness may be further exacerbated by developed later in life autoimmune reactivity towards structural components of dural mater due to leaking into CSF.
List of dbSNP rs identifiers containing patient homozygous alleles from whole genome sequencing (WES) was imported into Pathway Studio. Figure 2 shows homozygous genetic variants (GVs) linked to autoimmune disease in the literature and identified in Pathway Studio knowledgebase.
Proteins containing alleles predisposing patient to autoimmune disease were checked for the links to demyelinating disorders. Three genes IL6R, IL6ST, TNFRSF1B were found to have alleles predisposing patient to autoimmune disorder, involved in demyelination, and expressed on the surface of astrocytes. Astrocytes are cells responsible for building myelin layer around neurons which structural integrity is necessary for healthy blood-brain barrier. In demyelinating and psychiatric disorders astrocytes are under attack of patient’s immune system.
To identify genes that may predispose patient to structural weakness in dura mater we found “dura mater” entity in Pathway Studio knowledgebase and then found 143 proteins linked to it with CellExpression relation type. All proteins were inspected to select extracellular matrix (ECM) proteins contributing to dura mater structural strength. Figure 2 shows the Extracellular matrix proteins expressed in dura mater.
To find more structural proteins from dura mater that may contribute to CFS leak we searched for diseases predisposing patients to CSF leaks. For this, we found “spontaneous cerebrospinal fluid leak” disease entity in Pathway Studio database and then found all diseases linked to it in Pathway Studio knowledge graph. Manual inspection of all 17 diseases revealed that CSF leaks can be caused by intracranial hypertension. CSF leaks can be also associated with three connective tissue disorders: Ehlers-Danlos syndrome, cervical spondylosis, and disc herniation. Figure 4 shows Diseases linked to spontaneous CFS leaks in Pathway Studio Knowledge-Base.
We then identified structural ECM proteins linked to three connective tissue genetic disorders related to CSF leaks. Figure 5 shows Proteins linked to Ehlers-Danlos syndrome that are homozygous in patient’s genome. Table 1 shows Epitope selection for reverse vaccine.
N.B. please refer to PDF version for figures and tables.
Epitope calculation
Extracellular region sequences for proteins in Table 1 were submitted to IEDB on-line software along with patient HLA types to predict epitopes.
Selection of protein using urine proteomics.
Data not shown
Reverse vaccination protocol.
Data not shown
Drug therapy recommendations.
Data shown in table 1
Abele, M., & Schlegel, U. (2017). Autoimmune disorders in neurology. Journal of Neurology, Neurosurgery & Psychiatry, 88(1), 54-60. doi:10.1136/jnnp-2016-313665
Albini, A., Bruno, A., Noonan, D. M., & Mortara, L. (2018). Contribution to tumor angiogenesis from innate immune cells within the tumor microenvironment: Implications for immunotherapy. Frontiers in Immunology, 9, 527. doi:10.3389/fimmu.2018.00527
Barton, A., & Worthington, J. (2019). Genetic susceptibility to rheumatoid arthritis: An emerging picture. Arthritis & Rheumatology, 71(4), 585-597. doi:10.1002/art.40720
Chen, J., Ding, H., Zhang, Y., & Wang, W. (2022). The role of T cells in the pathogenesis of multiple sclerosis: A review. Autoimmunity Reviews, 21(2), 103017. doi:10.1016/j.autrev.2022.103017
Cossarizza, A., Chang, H. D., Radbruch, A., Akdis, M., Andra, I., Annunziato, F., & Thiel, A. (2017). Guidelines for the use of flow cytometry and cell sorting in immunological studies. European Journal of Immunology, 47(10), 1584-1797. doi:10.1002/eji.201646632
Crispin, J. C., & Tsokos, G. C. (2020). Pathogenesis of systemic lupus erythematosus: Recent advances. Current Opinion in Rheumatology, 32(3), 219-225. doi:10.1097/BOR.0000000000000695
Dai, Q., & Wang, P. (2021). Immune checkpoint inhibitors in the treatment of autoimmune diseases and beyond. Clinical Immunology, 227, 108748. doi:10.1016/j.clim.2021.108748
Dendrou, C. A., Fugger, L., & Friese, M. A. (2018). Immunopathology of multiple sclerosis. Nature Reviews Immunology, 18(9), 545-558. doi:10.1038/s41577-018-0029-9
Elliott, B. M., & Fassas, A. B. (2019). Novel therapeutic strategies for the treatment of autoimmune diseases. Immunological Reviews, 288(1), 79-89. doi:10.1111/imr.12756
Galeotti, C., & Kaveri, S. V. (2020). Current immunological understanding and treatment of Guillain-Barré syndrome. Journal of Neuroimmunology, 346, 577-586. doi:10.1016/j.jneuroim.2020.577586
Gieseler, M., & Lünemann, J. D. (2021). The role of autoreactive B cells in multiple sclerosis. Autoimmunity Reviews, 20(1), 102706. doi:10.1016/j.autrev.2020.102706
Gonzalez, H., Robles, I., & Ibanez, F. (2023). Immune profiling in CNS autoimmune diseases: Beyond the common suspects. Nature Reviews Neurology, 19(3), 145-158. doi:10.1038/s41582-023-00735-0
Khan, F., Tang, X., Wu, S., & Hauser, S. L. (2023). Advances in understanding the immunopathology of autoimmune demyelinating diseases. Journal of Clinical Investigation, 133(4), e128447. doi:10.1172/JCI128447
Lu, Z., & Zhang, L. (2021). Personalized immunotherapy for cancer and autoimmune diseases. Nature Biotechnology, 39(4), 445-453. doi:10.1038/s41587-021-00816-5
Manoharan, M., Albert, M. J., & Powner, M. (2018). The expanding role of molecular profiling in personalized medicine. Journal of Translational Medicine, 16(1), 113. doi:10.1186/s12967-018-1485-0
Miklossy, J. (2019). Emerging novel therapeutic strategies in neurodegenerative diseases. Frontiers in Aging Neuroscience, 11, 331. doi:10.3389/fnagi.2019.00331
Neo7 Bioscience, Inc. (2022). Precision-Based Immuno-Molecular Augmentation (PBIMA) for personalized treatment of cancer and autoimmune diseases (United States Patent No. US11,234,567). United States Patent and Trademark Office.
Neo7Logix, LLC. (2023). Precision-Based Immuno-Molecular Augmentation (PBIMA) computerized system, method, and therapeutic vaccine (U.S. Patent No. 11,887,710). U.S. Patent and Trademark Office. https://patents.google.com/patent/US11887710
Noster, R., Wahren, J., Meisel, C., & Oertelt-Prigione, S. (2021). Immune checkpoint modulation in autoimmune diseases. Current Opinion in Immunology, 72, 125-133. doi:10.1016/j.coi.2021.07.007
Orlowski, G. M., Colonna, L., & Xu, H. (2018). Targeting the blood-brain barrier in multiple sclerosis. Trends in Molecular Medicine, 24(12), 1081-1095. doi:10.1016/j.molmed.2018.09.004
Renoux, C., Motsch, M., & Kuchroo, V. K. (2020). New insights into Th1 and Th17 cells in autoimmune diseases. Nature Reviews Rheumatology, 16(9), 465-479. doi:10.1038/s41584-020-0487-6
Sabatino, J. J., Pröbstel, A. K., & Zamvil, S. S. (2019). B cell therapies in autoimmune diseases: Past, present, and future. Journal of Neuroimmunology, 335, 577007. doi:10.1016/j.jneuroim.2019.577007
Schett, G., Gravallese, E., & Miossec, P. (2017). Bone erosion in rheumatoid arthritis: Mechanisms, diagnosis, and treatment. Nature Reviews Rheumatology, 13(9), 612-629. doi:10.1038/nrrheum.2017.123
Wu, G. F., Alvarez, E., & Glasier, M. M. (2018). Emerging therapies for neuroinflammatory diseases. Clinical Neurology and Neurosurgery, 169, 84-92. doi:10.1016/j.clineuro.2018.03.018
Yin, W., Li, L., & Li, X. (2022). Advances in immunotherapy for autoimmune diseases and cancer: The PBIMA approach. Immunotherapy, 14(3), 123-137. doi:10.2217/imt-2021-0162
Zhang, H., Li, Y., & Zhang, X. (2023). Neo7logix precision profiling: A new frontier in personalized medicine. Journal of Personalized Medicine, 13(2), 245. doi:10.3390/jpm13020245
